EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans

Sarah F Andrews iD, Lauren Y Cominsky, Geoffrey D Shimberg iD, Rebecca A Gillespie iD, Jason Gorman iD, Julie E Raab iD, Joshua Brand iD, Adrian Creanga iD, Suprabhath R Gajjala, Sandeep Narpala iD, Crystal S F Cheung, Darcy R Harris iD und 14 weitere

Science Translational Medicine · 2023

DOI: 10.1126/scitranslmed.ade4976 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Sarah F Andrews und 25 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20902, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 77 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current yearly seasonal influenza vaccines primarily induce an antibody response directed against the immunodominant but continually diversifying hemagglutinin (HA) head region. These antibody responses provide protection against the vaccinating strain but little cross-protection against other influenza strains or subtypes. To focus the immune response on subdominant but more conserved epitopes on the HA stem that might protect against a broad range of influenza strains, we developed a stabilized H1 stem immunogen lacking the immunodominant head displayed on a ferritin nanoparticle (H1ssF). Here, we evaluated the B cell response to H1ssF in healthy adults ages 18 to 70 in a phase 1 clinical trial (NCT03814720). We observed both a strong plasmablast response and sustained elicitation of cross-reactive HA stem–specific memory B cells after vaccination with H1ssF in individuals of all ages. The B cell response was focused on two conserved epitopes on the H1 stem, with a highly restricted immunoglobulin repertoire unique to each epitope. On average, two-thirds of the B cell and serological antibody response recognized a central epitope on the H1 stem and exhibited broad neutralization across group 1 influenza virus subtypes. The remaining third recognized an epitope near the viral membrane anchor and was largely limited to H1 strains. Together, we demonstrate that an H1 HA immunogen lacking the immunodominant HA head produces a robust and broadly neutralizing HA stem–directed B cell response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanAdolescentAdultAgedHumansMiddle AgedYoung AdultAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusHemagglutinins

Substanzen

Antibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusHemagglutininsInfluenza Vaccines

Autor:innen und Institutionen

  • Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20902, USA.

ORCID-Profile: Sarah F Andrews, Geoffrey D Shimberg, Rebecca A Gillespie, Jason Gorman, Julie E Raab, Joshua Brand, Adrian Creanga, Sandeep Narpala, Darcy R Harris, Tongqing Zhou, Ingelise Gordon, LaSonji Holman, Katherine V Houser, Barney S Graham, Peter D Kwong, Alicia Widge, Lesia K Dropulic, Masaru Kanekiyo, Adrian B McDermott

Zitieren

APA

Andrews, S. F., Cominsky, L. Y., Shimberg, G. D., Gillespie, R. A., Gorman, J., Raab, J. E., Brand, J., Creanga, A., Gajjala, S. R., Narpala, S., Cheung, C. S. F., Harris, D. R., Zhou, T., Gordon, I., Holman, L., Mendoza, F., Houser, K. V., Chen, G. L., Mascola, J. R., …, & McDermott, A. B. (2023). An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ade4976

Vancouver

Andrews SF, Cominsky LY, Shimberg GD, Gillespie RA, Gorman J, Raab JE, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.ade4976

BibTeX
@article{Andrews2023,
  author = {Andrews, Sarah F and Cominsky, Lauren Y and Shimberg, Geoffrey D and Gillespie, Rebecca A and Gorman, Jason and Raab, Julie E and Brand, Joshua and Creanga, Adrian and Gajjala, Suprabhath R and Narpala, Sandeep and Cheung, Crystal S F and Harris, Darcy R and Zhou, Tongqing and Gordon, Ingelise and Holman, LaSonji and Mendoza, Floreliz and Houser, Katherine V and Chen, Grace L and Mascola, John R and Graham, Barney S and Kwong, Peter D and Widge, Alicia and Dropulic, Lesia K and Ledgerwood, Julie E and Kanekiyo, Masaru and McDermott, Adrian B},
  title = {An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans},
  journal = {Science Translational Medicine},
  year = {2023},
  doi = {10.1126/scitranslmed.ade4976}
}
Kostenlos starten →